Vertex Pharmaceuticals
RANK
16
In the fall of 2019, Vertex launched Trikafta, the latest of its breakthrough therapies for people with cystic fibrosis. Capable of treating up to 90% of those who suffer from the progressive, life-threatening disease, the drug has already been used to treat thousands of patients in the U.S. and recently won approval in the EU. The company’s sales—$4.2 billion in 2019—have averaged 35% annual growth over the past three years. One setback: The biotech’s stock fell 23% in October after it scrapped a new drug in Phase II clinical trials.
Courtesy of Vertex
Company Information
As of 5/23/2022
Country
U.S.
Headquarters
Boston
Industry
Pharmaceuticals
CEO
Reshma Kewalramani
Website
Company Type
Public
Ticker
VRTX
Revenues ($M)
$7,574.4
Profits ($M)
$2,342.1
Market Value ($M)
$66,436.9
Employees
3,900
Market value as of March 31, 2022.
Future 50As of 12/3/20
Overall Score
23
Sector
Health Care
Historical Data
| Year | Revenues ($M) | Profits ($M) |
|---|---|---|
| 2019 | $3,454 | $2,215 |
| 2018 | $2,623 | $415 |
